Biblio
“Necroptosis and Alzheimer's Disease: Pathogenic Mechanisms and Therapeutic Opportunities.”, J Alzheimers Dis, vol. 94, no. s1, pp. S367-S386, 2023.
, “Neural Stem Cells in the Treatment of Alzheimer's Disease: Current Status, Challenges, and Future Prospects.”, J Alzheimers Dis, vol. 94, no. s1, pp. S173-S186, 2023.
, “Neuroinflammation: A Common Pathway in Alzheimer's Disease and Epilepsy.”, J Alzheimers Dis, vol. 94, no. s1, pp. S253-S265, 2023.
, “Neuropathologic Changes of Alzheimer's Disease and Related Dementias: Relevance to Future Prevention.”, J Alzheimers Dis, vol. 95, no. 1, pp. 307-316, 2023.
, “Neuropathology of Anti-Amyloid-β Immunotherapy: A Case Report.”, J Alzheimers Dis, vol. 93, no. 2, pp. 803-813, 2023.
, “Neuroprotective Effect of Phloretin in Rotenone-Induced Mice Model of Parkinson's Disease: Modulating mTOR-NRF2-p62 Mediated Autophagy-Oxidative Stress Crosstalk.”, J Alzheimers Dis, vol. 94, no. s1, pp. S109-S124, 2023.
, “Neuroprotective Mechanisms of Amylin Receptor Activation, Not Antagonism, in the APP/PS1 Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 91, no. 4, pp. 1495-1514, 2023.
, “Neuroprotective Properties of Eudesmin on a Cellular Model of Amyloid-β Peptide Toxicity.”, J Alzheimers Dis, vol. 94, no. s1, pp. S97-S108, 2023.
, “Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 1, pp. 359-372, 2023.
, “Non-Pharmacological Interventions for Feeding and Eating Disorders in Persons with Dementia: Systematic Review and Evidence Summary.”, J Alzheimers Dis, vol. 94, no. 1, pp. 67-88, 2023.
, “A Novel Strategy for Alzheimer's Disease Based on the Regulatory Effect of Amyloid-β on Gut Flora.”, J Alzheimers Dis, vol. 94, no. s1, pp. S227-S239, 2023.
, “Observed Improvement in Cognition During a Personalized Lifestyle Intervention in People with Cognitive Decline.”, J Alzheimers Dis, vol. 94, no. 3, pp. 993-1004, 2023.
, “Odor Discrimination as a Marker of Early Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 3, pp. 1169-1178, 2023.
, “Pathogenesis, Animal Models, and Drug Discovery of Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 4, pp. 1265-1301, 2023.
, “Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia.”, J Alzheimers Dis, vol. 94, no. s1, pp. S289-S308, 2023.
, “Pathological and Therapeutic Advances in Parkinson's Disease: Mitochondria in the Interplay.”, J Alzheimers Dis, vol. 94, no. s1, pp. S399-S428, 2023.
, “Patterns of Aging Changes in Bodyweight May Predict Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 1, pp. 163-170, 2023.
, “Phonological and Semantic Fluency in Alzheimer's Disease: A Systematic Review and Meta-Analysis.”, J Alzheimers Dis, vol. 95, no. 1, pp. 1-12, 2023.
, “Physical Activity for Cognitive Health: A Model for Intervention Design for People Experiencing Cognitive Concerns and Symptoms of Depression or Anxiety.”, J Alzheimers Dis, vol. 94, no. 2, pp. 781-799, 2023.
, “The PI3K/AKT Signaling Pathway and Caspase-3 in Alzheimer's Disease: Which One Is the Beginner?”, J Alzheimers Dis, vol. 92, no. 2, pp. 391-393, 2023.
, “Plasma Amyloid-β Homeostasis Is Associated with Body Mass Index and Weight Loss in People with Overweight and Obesity.”, J Alzheimers Dis, vol. 93, no. 2, pp. 653-664, 2023.
, “Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ 40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 93, no. 1, pp. 333-348, 2023.
, “Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 615-628, 2023.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Playing Russian Roulette with Alzheimer's Disease Patients: Do the Cognitive Benefits of Lecanemab Outweigh the Risk of Edema, Stroke and Encephalitis?”, J Alzheimers Dis, vol. 92, no. 3, pp. 799-801, 2023.
,